Table 4.
The trend of symptoms improvement and lab tests between the two groups.
| Adalimumab group | Total | Control group | Total | P-Value | |
|---|---|---|---|---|---|
| Fever baseline | 2 (6.06%) | 33 | 2 (5.88%) | 34 | 1 |
| Fever day 3 | 0 (0%) | 33 | 0 (0%) | 32 | – |
| Fever day 7 | 0 (0%) | 17 | 1 (6.25%) | 16 | 0.48 |
| Cough baseline | 21(61.76%) | 34 | 17(50%) | 34 | 0.32 |
| Cough day 3 | 13(39.39%) | 33 | 13(38.2%) | 30 | 0.75 |
| Cough day 7 | 2(5.88%) | 17 | 3 (43.33%) | 13 | 0.62 |
| Dyspnea baseline | 27 (79.41%) | 34 | 24 (70.5%) | 34 | 0.4 |
| Dyspnea day 3 | 14(42.42%) | 33 | 16 (53.33%) | 30 | 0.38 |
| Dyspnea day 7 | 2 (12.5%) | 16 | 1(7.69%) | 13 | 0.76 |
| Myalgia baseline | 3(9.09%) | 33 | 7 (20.58%) | 34 | 0.3 |
| Myalgia day 3 | 2(6.06%) | 33 | 6(20%) | 30 | 0.13 |
| Myalgia day 7 | 0 (0%) | 16 | 0(0%) | 13 | – |
| Chest pain baseline | 8 (24.24%) | 33 | 13 (38.23%) | 34 | 0.21 |
| Chest pain day 3 | 6 (18.18%) | 33 | 8 (26.66%) | 30 | 0.41 |
| Chest pain day 7 | 0 (0%) | 16 | 0(0%) | 13 | – |
| Headache baseline | 6 (18.18%) | 33 | 7 (20.58%) | 34 | 1 |
| Headache day 3 | 1(3.03%) | 33 | 2 (6.66%) | 30 | 0.6 |
| Headache day 7 | 0 (0%) | 16 | 0(0%) | 13 | – |
| Diarrhea baseline | 7 (21.21%) | 33 | 4 (11.76%) | 34 | 0.29 |
| Diarrhea day 3 | 3 (9.09%) | 33 | 0 (0%) | 30 | 0.24 |
| Diarrhea day 7 | 0 (0%) | 16 | 0(0%) | 13 | – |
| Sore throat baseline | 3 (9.09%) | 33 | 3 (8.82%) | 34 | 1 |
| Sore throat day 3 | 2 (6.06%) | 33 | 3 (10%) | 30 | 0.66 |
| Sore throat day 7 | 0 (0%) | 16 | 0(0%) | 13 | – |
Data are presented as Mean ± SD; CRP: C-Reactive Protein; IL-6: Interleukin-6